此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities

2026年7月1日 更新者：University of California, San Francisco

Prostate Cancer (PC) is the most common non-cutaneous malignancy diagnosed and second leading cause of cancer death among men across the United States. PC among Black men accounts for a higher proportion alike of cancer diagnoses and deaths. In the prostate specific antigen (PSA)-based screening era, mortality rates improved at a similar velocity among Black and White men, but the 2- to 3-fold excess mortality burden borne by Black men has persisted over the past 40 years, the second highest among all major cancers. In recent years mortality is rising among Black men, and at a rapid velocity.

The explanations for this disparity-the extent to which it is attributable to genetics, environmental factors including Structural and Social Determinants of Health (SSDH), or access to care-are multifactorial and have been elucidated to a limited extent. A large meta-analysis recently found that across dozens of studies and cohorts, greater adjustment for clinical and SSDH factors generally resulted in race itself dropping as a significant predictor.

These and other findings suggest that the determinants of disparity be identified at time of, and prior to, cancer diagnosis, and that both genetic and environmental factors contribute to earlier development and progression.

研究概览

地位

招聘中

条件

干预/治疗

详细说明

The investigators hypothesize that SSDH factors drive cancer development differentially by race, and including SSDH factors in prediction models can improve risk prediction to guide decision-making regarding screening, diagnosis, and treatment across race and ethnic groups.

PRIMARY OBJECTIVE:

To identify not yet discovered SSDH and lifestyle factors that associate with identification of unfavorable vs. favorable prostate cancer histology between Black, Hispanic, and Asian men.

OUTLINE:

UCSF participants who agreed to participate in the Urology 90991 Biobank Consent (UCSF internal review board (IRB) #11-05226), and urology surgeons at community hospitals may refer participants for radical prostatectomy to University of California, San Francisco. Potential participants will be approached by the UCSF study team for an offer to participate and Non-UCSF participants will be asked to sign a medical release form prior to the research team collecting data from your medical record about your prostate cancer and treatment.

研究类型

观察性的

注册 (估计的)

350

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

  • 美国
    • California
      • San Francisco、California、美国、94143
        • 招聘中
        • University of California, San Francisco
        • 接触：
        • 接触：
        • 首席研究员：
          • Mathew Cooperberg, MD, MPH

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

Adult participants with prostate cancer with a planned RP scheduled to be performed at a University of California, San Francisco (UCSF) facility.

描述

Inclusion Criteria:

  • Participants who have elected radical prostatectomy as prostate cancer treatment.
  • Participants who have agreed to participate in the Urology Biobank.

Exclusion Criteria:

  • Participant does not plan nor schedule a radical prostatectomy (RP) procedure.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

队列和干预

团体/队列
干预/治疗
Men with prostate cancer
Participants who have planned or completed a non-investigational radical prostatectomy will be asked to complete a series of questionnaires online covering a subset of community-informed SSDH measures and individual exposures. Responses will be recorded in a secured database. . It will take about up to 2 hours to complete the surveys. There will be questions about your demographics (education level, income, employment, etc.); health care access and quality; lifestyle and behaviors. Data from your medical record about your prostate cancer and treatment will also be collected.
其他：Questionnaires
Participants will receive surveys to complete online via a secure system.
其他名称：
  • 调查
其他：Medical Record Review
Data will be collected from participants medical charts which includes disease history, pathological findings, and other disease characteristics.
其他名称：
  • 医疗图表审查

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Identification of not yet identified factors contributing to prostate cancer
大体时间：Up to 2 years
Genomic and SSDH factors will be evaluated to locate not yet identified factors that are associated with greater immune activation and prediction of unfavorable vs. favorable prostate cancer biology by race and ethnicity groups.
Up to 2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

University of California, San Francisco

合作者

National Cancer Institute (NCI)

调查人员

  • 首席研究员：Matthew Cooperberg, MD、University of California, San Francisco

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月31日

初级完成 (估计的)

2028年3月31日

研究完成 (估计的)

2028年3月31日

研究注册日期

首次提交

2026年7月1日

首先提交符合 QC 标准的

2026年7月1日

首次发布 (实际的)

2026年7月8日

研究记录更新

最后更新发布 (实际的)

2026年7月8日

上次提交的符合 QC 标准的更新

2026年7月1日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • 255517
  • U54CA302452 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

IPD 计划说明

De-identified data may be shared with study collaborators during the course of the study.

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅